Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and β-cell function in subjects with long-term remission

Diabetes Care

Volumn 34, Issue 8, 2011, Pages 1848-1853

  Hu, Yun ^a   Li, Lirong ^a   Xu, Yu ^a   Yu, Tingting ^a   Tong, Guoyu ^a   Huang, Hong ^a   Bi, Yan ^a   Weng, Jianping ^b   Zhu, Dalong ^a  

^a NANJING UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLICLAZIDE; GLUCOSE; INSULIN; ISOPHANE INSULIN; METFORMIN; RECOMBINANT HUMAN INSULIN; ANTIDIABETIC AGENT; HUMAN INSULIN; ISOPHANE INSULIN, HUMAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HOMEOSTASIS MODEL ASSESSMENT FOR INSULIN RESISTANCE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESPONSE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATIENT ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT DURATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; GLUCOSE INTOLERANCE; INSULIN RESISTANCE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN, ISOPHANE; INSULIN, REGULAR, HUMAN; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED;

EID: 84862832942     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-2105     Document Type: Article

References (25)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008;31(Suppl. 1):S55-S60
2. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003;46:3-19 (Pubitemid 36237741)
3. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Charles MA, Bennett PH. A two-step model for development of non-insulin-dependent diabetes. Am J Med 1991;90: 229-235
4. Nathan DM. Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 2002;347:1342-1349 (Pubitemid 35215326)
5. Qian L, Xu L, Wang X, et al. Early insulin secretion failure leads to diabetes in Chinese subjects with impaired glucose regulation. Diabetes Metab Res Rev 2009;25: 144-149
6. Alvarsson M, Sundkvist G, Lager I, et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 2003;26: 2231-2237 (Pubitemid 36993305)
7. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004; 27:1028-1032 (Pubitemid 38579760)
8. Li Y, Xu W, Liao Z, et al. Induction of longterm glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of β-cell function. Diabetes Care 2004;27:2597-2602 (Pubitemid 39441457)
9. Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD. Beneficial effects of insulin on glycemic control and β-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 2008; 31:1927-1932
10. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008;371:1753-1760 (Pubitemid 351697950)
11. McFarlane SI, Chaiken RL, Hirsch S, Harrington P, Lebovitz HE, Banerji MA. Near-normoglycaemic remission in African-Americans with type 2 diabetes mellitus is associated with recovery of beta cell function. Diabet Med 2001;18:10-16 (Pubitemid 32158102)
12. Samanta A, Burden AC, Jones GR, Clarkson L. The effect of short term intensive insulin therapy in non-insulin-dependent diabetics who had failed on sulphonylurea therapy. Diabetes Res 1986;3:269-271 (Pubitemid 16057253)
13. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of WHO consultation [Internet]. Available from http://www.staff.ncl.ac.uk/philip.home/who-dmg.pdf.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419 (Pubitemid 15018832)
15. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 1981;68: 1456-1467 (Pubitemid 12194400)
16. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992;15:318-368
17. Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 2001;24:89-94
18. Yki-Järvinen H, Esko N, Eero H, Marja-Riitta T. Clinical benefits and mechanisms of a sustained response to intermittent insulin therapy in type 2 diabetic patients with secondary drug failure. Am J Med 1988;84:185-192 (Pubitemid 18067428)
19. Glaser B, Leibovich G, Nesher R, Hartling S, Binder C, Cerasi E. Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes. Acta Endocrinol (Copenh) 1988;118:365-373
20. Pratipanawatr T, Cusi K, Ngo P, Pratipanawatr W, Mandarino LJ, DeFronzo RA. Normalization of plasma glucose concentration by insulin therapy improves insulin-stimulated glycogen synthesis in type 2 diabetes. Diabetes 2002;51:462-468 (Pubitemid 34764804)
21. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993;42: 1663-1672 (Pubitemid 23318125)
22. Wagenknecht LE, Mayer EJ, Rewers M, et al. The Insulin Resistance Atherosclerosis Study (IRAS) objectives, design, and recruitment results. Ann Epidemiol 1995; 5:464-472
23. Buchanan TA, Xiang AH, Peters RK, et al. Response of pancreatic β-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. Diabetes 2000;49:782-788 (Pubitemid 30339994)
24. Mittelman SD, Van Citters GW, Kim SP, et al. Longitudinal compensation for fatinduced insulin resistance includes reduced insulin clearance and enhanced β-cell response. Diabetes 2000;49:2116-2125
25. Bergman RN, Ader M, Huecking K, Van Citters G. Accurate assessment of beta-cell function: the hyperbolic correction. Diabetes 2002;51(Suppl. 1):S212-S220 (Pubitemid 34761518)